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Drugs are an increasingly salient concern in many prisons around the world. Specific prison drug 
policies are made, drugs are illegally used and legally prescribed, drug use and drug sale is 
sanctioned, drug profits are generated, and drug use is an important public health and treatment 
priority in most prisons. A growing number of prisoners are using drugs and a large proportion of 
people who use drugs have been in prison. As a consequence of such developments, everyday life in 
many prisons is dictated by drug related issues. The purpose of this Special Issue is to critically 
examine and advance research relating to the growth in use, control and treatment of drugs within 
the prison environment as well as research on relevant governmental policies and practices.  The 
articles highlight a diverse range of issues including the dynamic nature of the drugs problem in 
prison in relation to the substances being used, how they are administered, the meanings and 
motives associated with drug use and dealing and the way in which the drug market operates, but 
also the ways in which supply reduction, demand reduction and harm reduction responses have 
developed within different prison settings. The papers draw on a range of different quantitative and 
qualitative research designs and methodologies, highlighting the voices of the prisoners themselves 
as well as the practitioners and policy makers who are tasked with dealing with the problem of 
drugs in prisons. 
Studies in many countries have found an over-representation of drug users in prisons and that 
prisoners have higher rates of lifetime drug use, injecting drug use and problematic drug use 
compared to the general population (Boys et al., 2002; Fazel et al., 2006; Ministry of Health, 2006; 
CASA, 2010; EMCDDA, 2012; AIHW, 2013). However, as argued by Duke and Kolind (2016), the 
data available on drug use and drug users in prisons have a number of limitations in relation to 
validity and reliability. This is due to the sensitive nature of the topic (i.e. an illegal, stigmatised 
activity), the rules and surveillance within the prison environment and the reluctance of prisoners to 
self-report such activities for fear of further surveillance, sanctions and punishment. The 
methodological problems also create ethical issues for researchers in terms of compromising 
individual prisoner confidentiality and anonymity by exposing drug use patterns in individual 
prisons, particularly in small jurisdictions. For example, Codd et al. (2016, this Issue) found that 
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drug use is a significant problem among Irish prisoners, but only in particular prisons. If 
characteristics of the prisons and prisoners were used to describe drug use, their research carried the 
risk of exposing the identities of individual prisoners. Therefore, they employed hierarchical cluster 
analysis as a system to categorise prisons by drug use patterns of inmates and to facilitate tailored 
planning of service provision, without compromising individual prisoner confidentiality or 
anonymity. 
Prisons are high risk environments for initiation into drug use or for starting to use drugs again after 
a period of abstinence, for more unsafe forms of drug using behaviour, and for transmission of HIV 
and other blood borne infection; the rates of HIV and Hepatitis C infection are significantly higher 
among prisoners than the general population (Strang et al., 2006; Stöver & Weilandt, 2007; Indig et 
al., 2010). In particular, prisoners have much higher rates of reported experience of heroin use 
compared to the general population (EMCDDA, 2012; Ministry of Justice, 2010; Butler et al., 
2011). However, upon entry into prison, heroin users may switch opiates as a result of changes in 
availability within the prison setting. For example, Mohammed et al. (2016, this Issue) highlight the 
problem of prisoners switching to using prescribed buprenorphine intra-nasally in British prisons. 
As a result, buprenorphine-naloxone increasingly has been used as a treatment for opiate 
maintenance. The authors explore the experiences and perceptions of the effects of intranasal 
misuse of buprenorphine-naloxone within a prison setting and the implications for policy and 
practice.  
Prisoners who continue to inject in prison often do so in a more high risk fashion by sharing 
syringes which increases the risk of infection (Kerr et al, 2004; AIHW, 2013). For these reasons, it 
is of utmost importance to implement effective harm reduction strategies in prisons. This has been 
recognised since 1991 by the World Health Organisation (WHO) when it recommended the 
provision of sterile injecting equipment in prisons (WHO, 2004). However, as argued by Stöver and 
Hariga (2016, this Issue), harm reduction, and especially needle exchange programs, are still highly 
controversial in prisons even after twenty-five years of implementation and evidence of their 
efficacy. Moreover, as outlined in Moazen et al.’s study (2016, this Issue), which focuses on Iran (a 
country with experience of needle exchange programs in prisons), there are still obstacles to the 
provision of harm reduction strategies in prisons as expressed by the views of prison managers and 
health staff, many of whom are rather ambivalent towards needle exchange programs. 
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In relation to the social, health and demographic characteristics of drug users in prisons, they also 
fare worse off than the general population. Drug using prisoners have generally experienced 
deprivation, low educational achievement, unemployment, and problems with stable housing 
(EMCDDA, 2012). The complex needs of prisoners accessing drug and alcohol services in English 
prisons is elaborated on by McKeganey et al. (2016, this Issue). They describe the characteristics of 
prisoners entering enhanced drug and alcohol treatment within the newly established Drug 
Recovery Wings in England and Wales. Their analyses reveal that the group had wide ranging 
needs in relation to their substance use, mental health, attitudes to criminality and motivations for 
treatment. Their recovery from problematic drug and alcohol use and desistance from crime 
requires not only effective drug and alcohol treatment services, but also a wide range of support and 
interventions to tackle their complex needs both in prison and on release in the community (see 
also: Neale et al., 2015). 
Prisoners suffer poor physical and mental health including infectious diseases such as HIV/AIDS, 
Hepatitis C and B, and psychiatric co-morbidity such as personality and post-traumatic stress 
disorders and psychosis (WHO, 2014). Risk of suicide in prison may be particularly high for 
prisoners with drug problems (Fazel et al., 2011). There are also high rates of problem drinking and 
smoking within prison populations (AIHW, 2013; CASA, 2010; Ministry of Health, 2006). 
Research also indicates high rates of drug related deaths, particularly opioid overdoses, on release 
from prison (Farrell & Marsden, 2008). Finally, women prisoners are more likely to have serious 
drug related health problems (Fazel et al., 2006) and infectious disease than men (UNODC, 2008). 
Responding to such drug-related issues has become an important public health priority in prisons 
throughout the world. For example, in the most recent EU Drug Strategy and Action Plan for 2013-
2020, a key action is to ‘scale up the development, availability and coverage of health care 
measures for drug users in prison and after release with the aim of achieving a quality of care 
equivalent to that provided in the community’ (European Commission, 2012, C402/4, para 19.6). 
However, as demonstrated by Zurhold and Stöver (2016) in this issue, in a survey of 27 European 
countries, improvements in the quality, availability and access to health care are still necessary in 
order to make evidence-based drug treatment and harm reduction available in the prison setting and 
to ensure access to these services to all prisoners in need of them (see also Michel et al., 2015). 
Compared with the extensive research on prevalence and patterns of drug use in prisons, qualitative 
research exploring the meanings and motives of drug use in prison settings have been less 
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prominent (Mjåland, 2016, this Issue). Explanations of prisoners’ drug use in prisons have shown 
how it can be understood as a response to the ‘pains of imprisonment’(Sykes, 1958) encountered by 
the prisoners, such as boredom, violence, deprivation of personal autonomy, and denial of important 
social relations. Drugs like heroin and cannabis are preferred due to their sedative and analgesic 
effects to relieve stress, to facilitate sleep, to deal with the boredom of ‘doing time’ and ultimately 
to relieve pains of imprisonment (Boys et al., 2002; Cope, 2003; Ritter, Broers & Elger, 2013; 
Kolind, 2015). In this way, drug use is analysed as a way of coping or as self-medication. However, 
as Kolind et al. (2016) show in this Issue, drugs take on a range of different overlapping meanings 
highly influenced by the different institutional arrangements of the prison; and drugs as medicine 
(including drugs used for self-medication) is one of them. Moreover, drugs also take on meaning as 
illegal substances and as a constrainer of desirable self-development in drug therapy and treatment. 
The authors also argue that the different practices and rationalizations attached to drugs in prison 
inform different prisoner subjectivities: the criminal subject of illegal drug use, the sick subject of 
therapeutic drug use, and the subject of self-improvement enacted through drug treatment. 
Prison drug use nonetheless, is not merely part of individual prisoners’ coping strategies. It also has 
to be understood in light of the everyday social lives within prison: the prisoner culture, social 
networks, economics, cultural capital, and so on (Wheatley, 2007: 403-406). Crewe (2005; 2006), 
for instance, has shown that drug use and dealing tend to accentuate existing inequalities in prisons 
between powerful and more vulnerable prisoners, and also contribute to the prison becoming a low 
trust environment. Although less antagonistic cultures of (drug) sharing within prisons have also 
been documented (Mjåland, 2014; see also: Sandøy 2015). Drug supply and dealing in prisons are 
therefore understood as more than simply economic activities. Drug selling is also strongly bound 
up with masculinity, self-identity, and internal hierarchies, and thus plays a role in creating 
important social and personal interactions in the prison. Tompkins (2016) in this Issue identifies 
two systems of drug selling in prison: Established Enterprises and Separate Suppliers. The first is 
organized and related to drug sellers and gang structures outside prisons whereas the second is more 
spontaneous, individual and opportunistic, and an increasing range of prisoners have taken up this 
route/strategy. Especially for the Separate Suppliers, drug dealing is used in order to enhance the 
dealers’ status and symbolic capital (i.e. by being able to bring drugs into prisons, making 
connections to outside drug and criminal networks, and displaying courage) and the feeling among 
prisoners that they are part of a larger social network. This is also in line with Mjåland’s (2016) 
findings in this Issue. Similarly, he found that prisoners who distributed and also shared drugs could 
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earn respect. In addition, drug trafficking could also carry subversive meanings for prisoners in a 
highly controlled and stigmatised environment. In fact, he found vibrant drug subcultures existing 
among prisoners who participated in the drug rehabilitation programmes under study. In sum, drugs 
in the prison market is a profitable commodity (either economically or in terms of symbolic capital) 
with a powerful influence on the prison environment.  
Criminal justice systems and prison settings differ markedly from country to country. 
Commentators have for instance raised concerns about mass incarceration in countries like the US 
or Russia, or highlighted assumable lenient penal practices related to ‘Scandinavian exceptionalism’ 
(Pratt, 2008). Despite such difference, most governments around the world have responded to the 
growing presence of drugs and drugs problems in prisons with increased control and sanctions. 
These policy developments in prisons are often influenced by the general thrust of wider national 
drugs and criminal justice policy and practice frameworks. As Mazhnaya et al. (2016) show in this 
Issue, national drug policy and law enforcement practice in the Ukraine clearly influence the cycles 
of imprisonment-release-imprisonment among people who use drugs. After prison-release, the 
confluence of police surveillance and societal stress contributed to Mazhnaya el al.’s research 
participants’ drug use relapse, perpetuating a cycle of searching for money and drugs, followed by 
re-arrest and re-incarceration. Especially important in this respect is to understand how law 
enforcement policies and practices contribute to the low rates of utilisation of opioid agonist 
therapies in the Ukraine. Fear of police and arrest contributes to avoiding opioid agonist therapies 
since system-level requirements identify clients accessing these treatments as targets for police 
harassment (see also: Bojko et al., 2015)  
Other countries however, have also increasingly implemented successful drug treatment and health 
programmes in prisons. For example, Elison et al. (2016, this Issue) report on the positive potential 
of the Breaking Free Online programme in supporting prisoners to begin the process of recovery 
from substance use in prison settings. Although the authors conclude that recovery may only be 
optimal if the appropriate support around issues, such as accommodation and employment, is 
provided upon release to the community. However, what we have also seen in many countries is a 
dual prison drug policy: increased control and increased drug treatment (Duke, 2003). In political 
discourse such dual policy is at times presented as beneficial and mutually supportive (Kolind et al., 
2013). In particular, it is argued that increased control will force drug users to enter into drug 
rehabilitation programmes, and conversely, that such programmes can help fulfil the political aims 
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of zero tolerance towards drugs. In this way, prison drug policy is to be seen as a clear product of its 
time (Garland, 2001a).  
In a study of the recent ‘criminal justice turn’ in British drug policy (i.e. away from former penal-
welfare thinking and the focus on rehabilitation (Garland, 2001b)), Seddon et al. (2012) among 
others, argue that this development relates to a more general societal shift characterized by a 
preoccupation with risk and security influenced by the neo-liberal principles of efficient 
management of welfare services. Increasingly, drug problems, as well as social problems more 
generally, are understood, tackled as well as produced within this framework of risk and risk 
management (see also: Bullock, 2011) and a criminalization of drug problems and policy (Duke, 
2006). However, as suggested by Hardy (2013) and by the various articles in this Special Issue it 
may be more correct to see the prison as being in a state of flux, characterized not by a wholesale 
rejection of the penal-welfare ideal, but by a mixture of welfare, risk and security. Rarely, however, 
is the mass incarceration of people who use drugs in itself questioned in official policy; neither 
ethically nor as being an effective strategy to reduce drug-related harms in prisons and society. It is 
clear that drugs and drug use will endure both in prisons and the community, so perhaps the best 
strategy is to simply reduce the number of drug users sentenced to prisons. 
 
References 
 
Australian Institute of Health and Welfare (AIHW) (2013). The Health of Australia’s Prisoners 
2012.  Canberra: AIHW. 
 
Bojko, M. J., Mazhnaya, A., Makarenko, I., Marcus, R., Dvoriak, S., Islam, Z., & Altice, F. L. 
(2015). “Bureaucracy & Beliefs”: Assessing the barriers to accessing opioid substitution 
therapy by people who inject drugs in Ukraine. Drugs: education, prevention and policy, 22, 
255-262. 
 
Boys, A., Farrell, M., Bebbington, P., Brugha, T., Coid, J., Jenkins, R., Lewis, G., Marsden, J., 
Meltzer, H., Singleton, N. & Taylor, C. (2002). Drug use and initiation in prison: results 
from a national prison survey in England and Wales. Addiction, 97, 1551-1560. 
 
Bullock, K. (2011). The construction and interpretation of risk management technologies in 
contemporary probation practice. British Journal of Criminology, 51, 120-135. 
 
7 
 
Butler, T., Lim, D. &  Callendar, D. (2011). National prison entrants’ bloodborne virus and risk 
behaviour survey 2004, 2007, and 2010. Sydney: The Kirby Institute (University of New 
South Wales) and National Drug Research Institute (Curtin University). 
 
CASA (2010). Behind Bars II: substance abuse and America’s prison population. New York: The 
National Center on Addiction and Substance Abuse at Columbia University (CASA). 
 
Codd, M., Mehegan, J., Kelleher, C. & Drummond, A. (2016). Use of hierarchical cluster analysis 
to classify prisons in Ireland into mutually exclusive drug-use risk categories.  Drugs: 
education, prevention and policy (this issue). 
 
Cope, N. (2003). ‘It's No Time or High Time’: Young Offenders' Experiences of Time and Drug 
Use in Prison. The Howard Journal of Criminal Justice, 42, 158-175. 
 
Crewe, B. (2005). Prisoner society in the era of hard drugs. Punishment & Society, 7, 457-481. 
 
Crewe, B.(2006). Prison drug dealing and the ethnographic lens. The Howard Journal of Criminal 
Justice, 45, 347-368. 
 
Duke, K. (2003). Drugs, Prisons and Policy-Making, New York, Palgrave Macmillan. 
 
Duke, K. (2006). Out of crime and into treatment? The criminalisation of contemporary drugs 
policy since Tackling Drugs Together. Drugs: education, prevention and policy, 13, 409-
415. 
 
Duke, K. (2011). Reconceptualising harm reduction in prisons. In: Fraser, S. & Moore, D. (eds)  
The Drug Effect: Health, Crime and Society.  Cambridge: Cambridge University Press. 
 
Duke, K. (2013). From crime to recovery: the reframing of British drugs policy?  Journal of Drug 
Issues, 43, 39-55. 
 
Duke, K. & Kolind, T. (2016). ‘The prison population and drug use’, in Kolind, T., Thom, B. & 
Hunt, G. (eds.) Handbook on Drug and Alcohol Studies – social science perspectives, 
Volume 1, London: Sage. In press. 
 
Elison, S., Weston, S., Davies, G., Dugdale, S., & Ward, J. (2016). Findings from mixed-methods 
feasibility and effectiveness evaluations of the ‘Breaking Free Online’ treatment and 
recovery programme for substance misuse in prisons. Drugs: education, prevention and 
policy, this issue. 
 
European Commission (2012). EU Drugs Strategy (2013-2020). Brussels: European Commission.   
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2012:402:0001:0010:en:PDF 
 
EMCDDA (2012). Prisons and Drugs in Europe: the problem and responses. Lisbon: EMCDDA. 
 
Farrell, M. & Marsden, J. (2008). Acute risk of drug-related death among newly released prisoners 
in England and Wales. Addiction, 103, 2251-255. 
  
8 
 
Fazel, S., Bains, P. & Doll, H. (2006). Substance abuse and dependence in prisoners: a systematic 
review. Addiction, 101, 181-191. 
 
Fazel, S., Grann, M. Kling, B., & Hawton, K. (2011). Prison suicide in 12 countries: an ecological 
study of 861 suicides during 2003-2007. Social Psychiatry and Psychiatric Epidemiology, 
46, 191-195. 
 
Garland, D. (2001a). The Culture of Control. Crime and Social Order in Contemporary Society, 
Oxford: Oxford University Press. 
 
Garland, D. (2001b). Punishment and Welfare. Aldershot: Gower. 
 
Hardy, M. (2013). Practitioner perspectives on risk: Using governmentality to understand 
contemporary probation practice. European Journal of Criminology, 11, 303-318. 
 
Indig, D., Topp, L., Ross, B., Mamoon, H., Border, B., Kumar, S. et al. (2010).  2009 NSW Inmate 
Health Survey: Key findings report. Sydney: Justice Health. 
 
Kerr, T., Wood, E., Betteridge, G., Lines, R., & Jurgens, R. (2004). Harm reduction in prisons: a 
‘rights based’ analysis. Critical Public Health, 14, 345-360. 
 
Kolind, T. (2015). Drugs and discretionary power in prisons: The Officer’s Perspective. 
International Journal of Drug Policy,  26, 799-807. 
 
Kolind, T., Frank, V. A., Lindberg, O. & Tourunen, J. (2013). Prison-based drug treatment in 
Nordic political discourse: An elastic discursive construct. European Journal of 
Criminology, 10, 659-674. 
Bojko, M. J., Mazhnaya, A., Makarenko, I., Marcus, R., Dvoriak, S., Islam, Z., & Altice, F. L. 
(2015). “Bureaucracy & Beliefs”: Assessing the barriers to accessing opioid substitution 
therapy by people who inject drugs in Ukraine. Drugs: Education, Prevention and Policy, 
22, 255-262. 
 
Mazhnaya, A., Bojko, M., Marcus, R., Filippovych, S., Islam, Z., Dvoriak, S., & Altice, F. (2016).  
In Their Own Voices: Breaking the Vicious Cycle of Addiction, Treatment and Criminal 
Justice Among People who Inject Drugs in Ukraine. Drugs: education prevention and 
policy. (this issue) 
 
McKeganey, N. et al (2016) The Characteristics of Prisoners Receiving Treatment within Drug 
Recovery Wings in England and Wales, Drugs: education, prevention and policy, (this 
issue). 
 
Michel, L., Lions, C., Van Malderen,  S., Schiltz, J., Vanderplasschen, W., Holm, K., Kolind, T., 
Nava, F., Weltzien, N., Moser, A., Jauffret-Roustide, M., Maguet, O., Carrieri, P., Brentari, 
C. & Stover, H. (2015). Insufficient access to harm reduction measures in prisons in 5 
countries (PRIDE Europe): a shared European public health concern. BMC Public Health, 
15: 1093. 
 
9 
 
Ministry of Justice (2010). Compendium of reoffending statistics and analysis. London: Ministry of 
Justice. 
 
Ministry of Health (2006). Results from the Prisoner Health Survey, 2005. Wellington, New 
Zealand: Ministry of Health. 
 
Moazen, B., Shahbazi, M., Rezaei, F., Shokouhi, M., Farnia, M., Moradi, G., & Dolan, K. (2016). 
Views of Prison Staff towards Needle Exchange Program in Prisons: A Qualitative Study in 
Iran, Drugs: education, prevention and policy. (this issue) 
 
Mohammed, Z., Hughes, G., Hearty, P., & Wright, N. (2016). The perceived and actual 
consequences of intranasal administration of buprenorphine or burprenorphine-naloxone by 
prisoners. Drugs: education, prevention and policy. (this issue) 
 
Mjåland, K. (2014). ‘A culture of sharing’: Drug exchange in a Norwegian prison. Punishment & 
Society 16, 336-352. 
 
Mjåland, K. (2016). Exploring prison drug use in the context of prison based drug rehabilitation. 
Drugs: education, prevention and policy. (this issue) 
 
Neale, J., Tompkins, C., Wheeler, C., Finch, E., Marsden, J., Mitcheson, L., Rose, D., Wykes, T., &  
Strang, J. (2015). “You’re all going to hate the word ‘recovery’ by the end of this”: Service 
users’ views of measuring addiction recovery. Drugs: Education, Prevention and Policy, 22, 
26-34. 
Pratt, J. (2008). Scandinavian Exceptionalism in an Era of Penal Excess. British Journal of 
Criminology, 48: 119-137. 
 
Ritter, C., Broers, B. & Elger, B. S. (2013). Cannabis use in a Swiss male prison: Qualitative study 
exploring detainees’ and staffs’ perspectives. International Journal of Drug Policy, 24, 573-
578. 
Sandøy, T. A. (2015). Group solidarity in a hostile milieu: Immigrant experiences in a street-based 
drug scene. Drugs: Education, Prevention and Policy, 22, 232-238. 
 
Seddon, T., Williams, L. & Ralphs, R. (2012). Tough choices. Risk, security, and the 
criminalization of drug policy. Oxford: Oxford University Press. 
 
Stöver, H. & Weilandt, C. (2007). Drug use and drug services in prison, in Moller, L., Stöver, H., 
Jurgens, R., Gatherer, A. & Nikogosian, H. (eds.) Health in prisons: a WHO guide to the 
essentials in prison health.  Copenhagen: WHO Regional Office for Europe (pp. 85-111). 
 
Stover, H. & Hariga, F. (2016). Prison-based needle and syringe programmes (PNSP) - still highly 
controversial after all these years. Drugs: education, prevention and policy. (this issue) 
 
Strang, J., Gossop, M., Heuston, J., Green, J., Whitely, C, & Maden, A. (2006) Persistence of drug 
use during imprisonment: relationship of drug type, recency of use, and severity of 
dependence to heroin, cocaine, and amphetamine in prison.  Addiction, 10, 1125-32. 
 
Sykes, G. (1958) The Society of Captives. Princeton: Princeton University Press. 
10 
 
 
Tompkins, C. (2016) ‘There’s that many people selling it:’ Exploring the Nature, Organisation and 
Maintenance of Prison Drug Markets in England. Drugs: education, prevention and policy. 
(this issue) 
 
UNODC (2008) Women and HIV in prison settings. Vienna: United Nations Office on Drugs and 
Crime. 
Wheatley, M. (2007). Drugs in prison. In: Jewkes, Y. (ed.) Handbook on prisons. Devon: Willan 
Publishing. Pp. 399-422. 
World Health Organization. (2004). Evidence for action on HIV/AIDS and injecting drug use. 
Policy brief: Provision of sterile injecting equipment to reduce HIV transmission. Geneva: 
World Health Organization. 
WHO (2014). Prisons and Health.  Copenhagen: WHO Regional Office for Europe. 
 
Zurhold, H. & Stover, H. (2016). Provision of harm reduction and drug treatment services in    
custodial settings - findings from the European ACCESS study. Drugs: education, 
prevention and policy. (this issue) 
